Here, we aim to examine the range of missing proportions of HRD samples across various three tumors where HRD is frequently reported (breast, ovarian and pancreas cancer) and determined the impact of cancer-type-specific thresholds as well as of promoter methylation BRCA1/RAD51C for an available subset of cases. This evidence concerns the gene RAD51C and cancer.